Search Results - "GUCKERT, Mary"

Dabrafenib in BRAF -mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial by Hauschild, Axel, Prof, Grob, Jean-Jacques, Prof, Demidov, Lev V, Prof, Jouary, Thomas, MD, Gutzmer, Ralf, MD, Millward, Michael, MD, Rutkowski, Piotr, PhD, Blank, Christian U, PhD, Miller, Wilson H, PhD, Kaempgen, Eckhart, PhD, Martín-Algarra, Salvador, PhD, Karaszewska, Boguslawa, MD, Mauch, Cornelia, Prof, Chiarion-Sileni, Vanna, MD, Martin, Anne-Marie, PhD, Swann, Suzanne, PhD, Haney, Patricia, BSN, Mirakhur, Beloo, PhD, Guckert, Mary E, MSN, Goodman, Vicki, MD, Chapman, Paul B, MD

“…Summary Background Dabrafenib, an inhibitor of mutated BRAF, has clinical activity with a manageable safety profile in studies of phase 1 and 2 in patients…”
Get full text

Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma by ASCIERTO, Paolo A, MINOR, David, HAMID, Omid, AMARAVADI, Ravi, SIMEONE, Ester, WILHELM, Tabea, KIM, Kevin B, LONG, Georgina V, MARTIN, Anne-Marie, MAZUMDAR, Jolly, GOODMAN, Vicki L, TREFZER, Uwe, RIBAS, Antoni, LEBBE, Celeste, O'HAGAN, Anne, ARYA, Niki, GUCKERT, Mary, SCHADENDORF, Dirk, KEFFORD, Richard F, GROB, Jean-Jacques

“…Dabrafenib (GSK2118436) is a potent inhibitor of mutated BRAF kinase. Our multicenter, single-arm, phase II study assessed the safety and clinical activity of…”
Get full text

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial by Long, Georgina V, Dr, Trefzer, Uwe, MD, Davies, Michael A, MD, Kefford, Richard F, Prof, Ascierto, Paolo A, MD, Chapman, Paul B, MD, Puzanov, Igor, MD, Hauschild, Axel, MD, Robert, Caroline, PhD, Algazi, Alain, MD, Mortier, Laurent, Prof, Tawbi, Hussein, PhD, Wilhelm, Tabea, MD, Zimmer, Lisa, MD, Switzky, Julie, MSN, Swann, Suzanne, PhD, Martin, Anne-Marie, PhD, Guckert, Mary, MSN, Goodman, Vicki, MD, Streit, Michael, MD, Kirkwood, John M, Prof, Schadendorf, Dirk, Prof

“…Summary Background Brain metastases are common in patients with metastatic melanoma and median overall survival from their diagnosis is typically 17–22 weeks…”
Get full text

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma by Plesner, Torben, Arkenau, Hendrik-Tobias, Gimsing, Peter, Krejcik, Jakub, Lemech, Charlotte, Minnema, Monique C., Lassen, Ulrik, Laubach, Jacob P., Palumbo, Antonio, Lisby, Steen, Basse, Linda, Wang, Jianping, Sasser, A. Kate, Guckert, Mary E., de Boer, Carla, Khokhar, Nushmia Z., Yeh, Howard, Clemens, Pamela L., Ahmadi, Tahamtan, Lokhorst, Henk M., Richardson, Paul G.

“…Daratumumab, a human CD38 immunoglobulin G1 kappa (IgG1κ) monoclonal antibody, has activity as monotherapy in multiple myeloma (MM). This phase 1/2 study…”
Get full text

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma by Dimopoulos, Meletios A., Oriol, Albert, Nahi, Hareth, San-Miguel, Jesus, Bahlis, Nizar J., Usmani, Saad Z., Rabin, Neil, Orlowski, Robert Z., Komarnicki, Mieczyslaw, Suzuki, Kenshi, Plesner, Torben, Yoon, Sung-Soo, Ben Yehuda, Dina, Richardson, Paul G., Goldschmidt, Hartmut, Reece, Donna, Lisby, Steen, Khokhar, Nushmia Z., O’Rourke, Lisa, Chiu, Christopher, Qin, Xiang, Guckert, Mary, Ahmadi, Tahamtan, Moreau, Philippe

Get full text

Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy by HERRSTEDT, Jørn, APORNWIRAT, Wichit, GRUNBERG, Steven M, SHAHARYAR, Ahmed, AZIZ, Zeba, ROILA, Fausto, VAN BELLE, Simon, RUSSO, Mark W, LEVIN, Jeremey, RANGANATHAN, Salabha, GUCKERT, Mary

“…The purpose of this phase III trial was to evaluate the efficacy and safety of regimens containing casopitant, a novel neurokinin-1 receptor antagonist, for…”
Get full text

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial by Grunberg, Steven M, Prof, Rolski, Janusz, MD, Strausz, Janos, MD, Aziz, Zeba, Prof, Lane, Stephen, MSc, Russo, Mark W, MD, Wissel, Paul, MD, Guckert, Mary, RN MSN, Wright, Oliver, MD, Herrstedt, Jørn, Prof

“…Summary Background Chemotherapy-induced nausea and vomiting (CINV) remains a clinical management problem after treatment with highly emetogenic chemotherapy…”
Get full text

PHASE 3 MAGNITUDE STUDY: RESULTS FROM SECOND INTERIM ANALYSIS OF NIRAPARIB WITH ABIRATERONE ACETATE AND PREDNISONE AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH AND WITHOUT HRR GENE ALTERATIONS by Rathkopf, Dana E, Small, Eric, Guckert, Mary, Chi, Kim N

“…In the primary analysis of the phase-3 MAGNITUDE study, Niraparib with abiraterone acetate and prednisone (NIRA+AAP) demonstrated significant improvement in…”
Get full text

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma by Dimopoulos, Meletios A, Oriol, Albert, Nahi, Hareth, San-Miguel, Jesus, Bahlis, Nizar J, Usmani, Saad Z, Rabin, Neil, Orlowski, Robert Z, Komarnicki, Mieczyslaw, Suzuki, Kenshi, Plesner, Torben, Yoon, Sung-Soo, Ben Yehuda, Dina, Richardson, Paul G, Goldschmidt, Hartmut, Reece, Donna, Lisby, Steen, Khokhar, Nushmia Z, O’Rourke, Lisa, Chiu, Christopher, Qin, Xiang, Guckert, Mary, Ahmadi, Tahamtan, Moreau, Philippe

“…The addition of daratumumab to lenalidomide and dexamethasone resulted in superior response rate and progression-free survival, as compared with lenalidomide…”
Get full text

FINAL ANALYSIS OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND HOMOLOGOUS RECOMBINATION REPAIR GENE ALTERATIONS RECEIVING FIRST-LINE NIRAPARIB WITH ABIRATERONE ACETATE PLUS PREDNISONE (MAGNITUDE STUDY) by Olivier, Kara, Smith, Matthew, Rathkopf, Dana E, Small, Eric, Guckert, Mary, Chi, Kim N

“…Addition of niraparib (NIRA) to first-line (1L) abiraterone acetate plus prednisone (AAP) significantly improved radiographic progression-free survival in…”
Get full text

PATIENTS RECEIVING SHORT RUN-IN TREATMENT (≤2 MONTHS) WITH ABIRATERONE ACETATE AND PREDNISONE (AAP) SHOWED SIMILAR BENEFIT FROM NIRAPARIB AND AAP IN THE PHASE 3 MAGNITUDE STUDY WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND HRR GENE ALTERATIONS by Smith, Matthew, Efstathiou, Eleni, Rathkopf, Dana E, Guckert, Mary, Chi, Kim N

“…In the phase 3 MAGNITUDE study, niraparib (NIRA) with abiraterone acetate and prednisone (AAP) significantly improved clinical outcomes in patients with…”
Get full text

Preclinical characterization of human Kallikrein 2 (hK2) as a novel target for the treatment of prostate cancer by Shen, Fei, Kelly, William Kevin, Pandit-Taskar, Neeta, McDevitt, Theresa, Smith, Ryan, Menard, Krista, Packman, Kathryn, Chaudhary, Ruchi, Rupnow, Brent, Yu, Margaret K., Guckert, Mary E., Tian, Shaozhou Ken, Chu, Gerald, Xie, Hong, Patricia, Daniel, Max, Steven I, Morris, Michael J.

“…202 Background: Treatment options that are durably effective for patients with metastatic (m) castration-resistant prostate cancer (CRPC) remain limited…”
Get full text

Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux by Moreau, Philippe, Kaufman, Jonathan L., Sutherland, Heather J., Lalancette, Marc, Magen, Hila, Iida, Shinsuke, Kim, Jin Seok, Prince, Miles, Cochrane, Tara, Khokhar, Nushmia Z, Guckert, Mary, Qin, Xiang, Oriol, Albert

“…Introduction: Daratumumab is an anti-CD38 IgGκ monoclonal antibody that has been combined successfully with lenalidomide and dexamethasone. The combination of…”
Get full text

Abstract 4133: High prevalence and heterogeneity of emergence of BRCA reversion mutations at progression on niraparib treatment in BRCA -mutant metastatic castration-resistant prostate cancer (mCRPC) patients by Urtishak, Karen, Attard, Gerhardt, Kanno, Tokuwa, Thomas, Shibu, Mason, Gary E., Espina, Byron, Zhu, Eugene, Hutnick, Natalie, Guckert, Mary, del Corral, Adam, Li, Mark, Lopez-Gitlitz, Angela, Chi, Kim, Kelly, William Kevin, Yu, Evan Y., Fizazi, Karim, Smith, Matthew

“…Abstract In the phase 2 GALAHAD study (NCT02854436), the PARP inhibitor (PARPi) niraparib, was evaluated in heavily pre-treated patients with mCRPC and…”
Get full text

Personalizing Research: Special Educators' Awareness of Evidence-Based Practice by Guckert, Mary, Mastropieri, Margo A., Scruggs, Thomas E.

“…Although evidence-based practices are considered critical to student success, a research-to-practice gap exists. This qualitative study examined practicing…”
Get full text

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux by Usmani, Saad Z, Dimopoulos, Meletios A, Belch, Andrew, White, Darrell, Benboubker, Lofti, Cook, Gordon, Leiba, Merav, Morton, James, Ho, P. Joy, Kim, Kihyun, Takezako, Naoki, Khokhar, Nushmia Z, Guckert, Mary, Wu, Kaida, Qin, Xiang, Casneuf, Tineke, Chiu, Christopher, Sasser, A. Kate, San-Miguel, Jesús

“…▪ Introduction: Daratumumab is a human monoclonal antibody targeting CD38 that demonstrated superior efficacy in combination with lenalidomide and…”
Get full text

Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux) and 54767414MMY3004 (Castor) by Palumbo, Antonio, Dimopoulos, Meletios A., Reece, Donna Ellen, Sonneveld, Pieter, Spencer, Andrew, Chanan-Khan, Asher Alban Akmal, Goldschmidt, Hartmut, Yeh, Howard, Schecter, Jordan Mark, Qin, Xiang, Amin, Himal, Guckert, Mary E., Ahmadi, Tahamtan, Orlowski, Robert Z.

“…Abstract only…”
Get full text

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503) by Plesner, Torben, Arkenau, Hendrik-Tobias, Gimsing, Peter, Krejcik, Jakub, Lemech, Charlotte, Minnema, Monique C., Lassen, Ulrik, Laubach, Jacob P., Palumbo, Antonio, Lisby, Steen, Basse, Linda, Wang, Jianping, Sasser, A Kate, Guckert, Mary E, Yeh, Howard, Ahmadi, Tahamtan, Lokhorst, Henk M., Richardson, Paul G.

“…▪ Introduction: Daratumumab (DARA) is a human anti-CD38 IgG1κ monoclonal antibody that showed synergistic anti-tumor activity in combination with lenalidomide…”
Get full text

Understanding Bystander Perceptions of Cyberbullying in Inclusive Classroom Settings by Guckert, Mary

“…Cyberbullying is a pervasive problem that puts students at risk of successful academic outcomes and the ability to feel safe in school. As most students with…”
Get full text

Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma by Plesner, Torben, Arkenau, Hendrik-Tobias, Lokhorst, Henk M., Gimsing, Peter, Krejcik, Jakub, Lemech, Charlotte Rose, Minnema, Monique, Lassen, Ulrik Niels, Ahmadi, Tahamtan, Yeh, Howard, Guckert, Mary, Brun, Nikolai C., Lisby, Steen, Basse, Linda, Palumbo, Antonio, Richardson, Paul G.

“…Abstract only…”
Get full text